Effect of Kou Yan Qing Ke Li on the prevention and treatment of radiation-induced oral mucositis in patients with nasopharyngeal carcinoma
10.7518/hxkq.2016.01.008
- VernacularTitle:口炎清颗粒防治鼻咽癌患者放射性口腔炎的疗效观察
- Author:
Yun GONG
1
;
Li ZHANG
;
Zehui FENG
;
Xudong HE
Author Information
1. 湖北医药学院附属东风医院肿瘤科
- Keywords:
Kou Yan Qing Ke Li;
nasopharyngeal carcinoma;
prevention;
radiation-induced oral mucositis
- From:
West China Journal of Stomatology
2016;(1):37-40
- CountryChina
- Language:Chinese
-
Abstract:
Objective The effect of Kou Yan Qing Ke Li on the prevention and treatment of radiation-induced oral mucositis was investigated in patients with nasopharyngeal carcinoma. Methods Sixty patients with nasopharyngeal carcinoma to be treated with radiotherapy were randomized into two groups: the experimental and control groups. The experimental group (30 patients) was treated with Kou Yan Qing Ke Li during the full course of radiotherapy. The control group (30 patients) rinsed their mouths in the same way with mouth washes containing 0.9% sodium chloride injection, lidocaine, dexamethasone, vitamin B12 and B2 gargle liquid mixture, when grade 2 and above radiation-induced oral mucositis appeared in the process of radiation. Radiation-induced oral mucositis was assessed according to the radiation therapy oncology group criteria. The time of occurrence and degree of pain grade were compared between the two groups. Results The first onset of oral mucositis in the experimental group (12.40 d±2.74 d) was later than that in the control group (9.46 d ± 1.39 d) (t=5.241, P<0.001), whereas the grade of pain and acute radiation mucositis was lower in the experimental group than that in the control group. The difference was statistically significant. Conclusion Kou Yan Qing Ke Li could delay the time of occurrence of radiation-induced oral mucositis, reduce the severity of radiation stomatitis, alleviate the pain of patients, improve the clinical symptoms of patients, and effectively prevent and treat radiation-induced oral mucositis in patients with nasopharyngeal carcinoma.
